These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 29318594)

  • 1. Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule.
    Liu J; Bihler H; Farinha CM; Awatade NT; Romão AM; Mercadante D; Cheng Y; Musisi I; Jantarajit W; Wang Y; Cai Z; Amaral MD; Mense M; Sheppard DN
    Br J Pharmacol; 2018 Apr; 175(7):1017-1038. PubMed ID: 29318594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
    Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
    J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms.
    Roxo-Rosa M; Xu Z; Schmidt A; Neto M; Cai Z; Soares CM; Sheppard DN; Amaral MD
    Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17891-6. PubMed ID: 17098864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CFTR potentiators partially restore channel function to A561E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-CFTR.
    Wang Y; Liu J; Loizidou A; Bugeja LA; Warner R; Hawley BR; Cai Z; Toye AM; Sheppard DN; Li H
    Br J Pharmacol; 2014 Oct; 171(19):4490-503. PubMed ID: 24902474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revertant mutants modify, but do not rescue, the gating defect of the cystic fibrosis mutant G551D-CFTR.
    Xu Z; Pissarra LS; Farinha CM; Liu J; Cai Z; Thibodeau PH; Amaral MD; Sheppard DN
    J Physiol; 2014 May; 592(9):1931-47. PubMed ID: 24591578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
    Liu J; Berg AP; Wang Y; Jantarajit W; Sutcliffe KJ; Stevens EB; Cao L; Pregel MJ; Sheppard DN
    Br J Pharmacol; 2022 Apr; 179(7):1319-1337. PubMed ID: 34644413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
    Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
    EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of the cystic fibrosis transmembrane conductance regulator Cl
    Wang Y; Cai Z; Gosling M; Sheppard DN
    Am J Physiol Lung Cell Mol Physiol; 2018 Nov; 315(5):L846-L857. PubMed ID: 30136610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
    Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
    Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the F508del mutation on ovine CFTR, a Cl- channel with enhanced conductance and ATP-dependent gating.
    Cai Z; Palmai-Pallag T; Khuituan P; Mutolo MJ; Boinot C; Liu B; Scott-Ward TS; Callebaut I; Harris A; Sheppard DN
    J Physiol; 2015 Jun; 593(11):2427-46. PubMed ID: 25763566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of Cystic Fibrosis Transmembrane Conductance Regulator Function in Human Bronchial Epithelial Cells via SLC6A14-Dependent Amino Acid Uptake. Implications for Treatment of Cystic Fibrosis.
    Ahmadi S; Wu YS; Li M; Ip W; Lloyd-Kuzik A; Di Paola M; Du K; Xia S; Lew A; Bozoky Z; Forman-Kay J; Bear CE; Gonska T
    Am J Respir Cell Mol Biol; 2019 Dec; 61(6):755-764. PubMed ID: 31189070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR.
    Bose SJ; Bijvelds MJC; Wang Y; Liu J; Cai Z; Bot AGM; de Jonge HR; Sheppard DN
    Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L71-L86. PubMed ID: 30969810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
    Matthes E; Goepp J; Carlile GW; Luo Y; Dejgaard K; Billet A; Robert R; Thomas DY; Hanrahan JW
    Br J Pharmacol; 2016 Feb; 173(3):459-70. PubMed ID: 26492939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
    Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells.
    Favia M; Mancini MT; Bezzerri V; Guerra L; Laselva O; Abbattiscianni AC; Debellis L; Reshkin SJ; Gambari R; Cabrini G; Casavola V
    Am J Physiol Lung Cell Mol Physiol; 2014 Jul; 307(1):L48-61. PubMed ID: 24816489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
    Yu W; Kim Chiaw P; Bear CE
    J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence assay for simultaneous quantification of CFTR ion-channel function and plasma membrane proximity.
    Prins S; Langron E; Hastings C; Hill EJ; Stefan AC; Griffin LD; Vergani P
    J Biol Chem; 2020 Dec; 295(49):16529-16544. PubMed ID: 32934006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
    Arora K; Naren AP
    Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue of functional F508del cystic fibrosis transmembrane conductance regulator by vasoactive intestinal peptide in the human nasal epithelial cell line JME/CF15.
    Rafferty S; Alcolado N; Norez C; Chappe F; Pelzer S; Becq F; Chappe V
    J Pharmacol Exp Ther; 2009 Oct; 331(1):2-13. PubMed ID: 19584307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.